Moogene Medi Co., Ltd.
Moogene Medi develops LNP-based nano-medicine, including hair-loss drug AD-303, cancer therapeutics, and functional cosmetics.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2016 and listed on KONEX in 2020, Moogene Medi is a nano-medicine firm using lipid nanoparticle (LNP) technology. It develops LNP-based drugs and cosmetics, including hair-loss treatment AD-303 (HUTERA), hair tonic, and skin boosters. AD-303 gained IND approval in August 2025, and Moogene Medi signed co-development deals with Yuhan, JW Pharmaceutical, and Medica Korea in December 2025 ahead of a 2026 trial with Adpharm.
Products & technology
- LNP raw materialsDelivery-vehicle raw materials for gene, protein, and compound therapeutics
- Topical hair-loss treatment AD-303 (HUTERA)Male pattern hair-loss treatment
- Colorectal and pancreatic cancer treatmentLNP-based cancer-targeted therapeutic delivery
- Hair tonicFunctional cosmetic for hair growth promotion
- Skin boosterFunctional cosmetic for whitening and wrinkle improvement
- Esthetic professional productsProfessional esthetic cosmetic products
- MD creamFunctional cosmetic cream
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2025 (Phase 1/2a 1)
- Phase 1/2aHutera D(AD-303)2025-08-14
4 trial sites
R&D and key agreements
Source: DART corporate disclosure대장암·췌장암 치료제(LNP 전달체) · 대장암, 췌장암 · Under development using a cancer-targeted LNP delivery system, being expanded to intractable diseases
바르는 탈모치료제 AD-303(HUTERA) · 남성형 탈모 · 1/2a 임상시험 예정(2026년 4월) · IND approved by MFDS on 2025-08-14; nonclinical work done in-house, clinical stage to proceed with Adpharm
희귀질환 mRNA 치료제 공동연구 · 희귀질환 · Joint research with a company holding rare-disease mRNA therapeutics; also strengthening collaboration on personalized cancer vaccines
C24 세라마이드 LNP · 피부 재생·상처 치유 · Research published in the journal Pharmaceutics; showed superior keratinocyte growth/migration promotion versus existing EGF treatment
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition